Liquidia inks $200M+ deal to expand drug portfolio

Liquidia is growing its portfolio for pulmonary hypertension treatments through a deal potentially worth well above $200M.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 29, 2023 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news